{"id":"NCT00898807","sponsor":"JHSPH Center for Clinical Trials","briefTitle":"Citalopram for Agitation in Alzheimer's Disease","officialTitle":"A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2013-09","completion":"2013-09","firstPosted":"2009-05-12","resultsPosted":"2014-06-27","lastUpdate":"2014-06-27"},"enrollment":186,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease","Agitation"],"interventions":[{"type":"DRUG","name":"citalopram","otherNames":["Celexa"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Citalopram and psychosocial intervention","type":"EXPERIMENTAL"},{"label":"Placebo and psychosocial intervention","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.","primaryOutcome":{"measure":"NeuroBehavior Rating Scale-- Agitation","timeFrame":"9 weeks","effectByArm":[{"arm":"Citalopram and Psychosocial Intervention","deltaMin":4.33,"sd":0.31},{"arm":"Placebo and Psychosocial Intervention","deltaMin":5.26,"sd":0.31}],"pValues":[{"comp":"OG000 vs OG001","p":"0.036"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":8,"countries":["United States","Canada"]},"refs":{"pmids":["22301195","24549548","24914549"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":94},"commonTop":["Confusion","Anxiety","Fatigue","Gait instability","Somnolence"]}}